Replies to post #466927 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Because everything NWBO has said is consistent with no TLD presented Tue, so it is only a matter of timing the run for the exits.

This statement is nonsensical. The below PR is not consistent with no TLD presented. The NYAS email concerning 'exciting' news in Dr. Liau's presentation is not consistent with no TLD presented. The near entirety of NWBO's board and employees attending the presentation is not consistent with no TLD. The attendance of the Flaskworks team is not consistent with no TLD presented. The attendance of long term survivors is not consistent with no TLD presented. The attendance of investors and journalists is not consistent with no TLD presented. Your statement ignores reality.

From the PR:

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
BETHESDA, Md., May 4, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled “Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma” will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.

Have a good one Ex. By.

Also, your double negatives really make these statements sound strange, but I kept with it ;D

[Nick119]

Lmao - This is 110% not accurate. Everything they've said IS consistent with TLD on Monday or Tuesday. I'd put money on Monday AM.

GFY - Have a great weekend.

[BetIsOn]

Ex,
Should the clinical trial new end points be updated by FDA proposed by NWBO or can be updated directly by NWBO after they did not get objection from FDA after a period of time?